Capstone Holding Corp（Capstone Therapeutics Corp）发布了其2026财年第一季度财务报告，业绩表现强劲。报告期内，公司实现营收同比增长60%，展现出了显著的市场扩张能力。更令人瞩目的是，其毛利润同比大幅跃升124%，增长速度远超营收增幅，这主要得益于运营效率的提升与成本结构的优化。
本季度，公司取得了过去四年中最佳的第一季度毛利率水平，这一关键指标的改善，凸显了其盈利能力的实质性增强。业绩的全面向好，反映了公司在战略执行和产品市场竞争力方面的持续进步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.